Zobrazeno 1 - 10
of 43
pro vyhledávání: '"A Comes Escoda"'
Autor:
Comes-Escoda, Ariadna, Villaronga-Flaqué, Miguel, Velasco-Arnaiz, Eneritz, Esteban, Elisabeth, Pertierra-Cortada, Àfrica, Noguera-Julian, Antoni
Publikováno v:
In Enfermedades infecciosas y microbiologia clinica (English ed.) January 2024 42(1):38-41
Autor:
Ariadna Comes-Escoda, Miguel Villaronga-Flaqué, Eneritz Velasco-Arnaiz, Elisabeth Esteban, Àfrica Pertierra-Cortada, Antoni Noguera-Julian
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421acb0093bb9e8d8999c4395900f3a4
https://doi.org/10.1016/j.eimc.2023.02.003
https://doi.org/10.1016/j.eimc.2023.02.003
Autor:
Anna Ruiz-Llobet, Ariadna Comes-Escoda, Edgar Zapico-Muñiz, Mireia Camós, Anna Faura, Susana Rives, Nuria Conde, J.L. Dapena, Sara Perez-Jaume, Montserrat Mesegué, Anna Alonso-Saladrigues, Albert Català
Publikováno v:
Hematological Oncology. 39:687-696
Asparaginase (ASP) is an essential component for the acute lymphoblastic leukemia (ALL) treatment, but toxicities, such as allergy, frequently limit its use. Although the potentially lower PEG-ASP formulation immunogenicity, few studies with conflict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d158ebcfc0848a10e60e2b13594250e
https://doi.org/10.1002/hon.2914
https://doi.org/10.1002/hon.2914
Autor:
null Montserrat Mesegué, null Anna Alonso‐Saladrigues, null Sara Pérez‐Jaume, null Ariadna Comes‐Escoda, null José Luís Dapena, null Anna Faura, null Nuria Conde, null Albert Català, null Anna Ruiz‐Llobet, null Edgar Zapico‐Muñiz, null Mireia Camós, null Susana Rives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b1e0f6a18c48c5fdeceb272079ca33
https://doi.org/10.1002/hon.2914/v3/response1
https://doi.org/10.1002/hon.2914/v3/response1
Autor:
Mesegue Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, José Luis Dapena Díaz, Faura A, Conde Cuevas N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M, Rives-Sola S
Publikováno v:
HEMATOLOGICAL ONCOLOGY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Asparaginase (ASP) is an essential component for the acute lymphoblastic leukemia (ALL) treatment, but toxicities, such as allergy, frequently limit its use. Although the potentially lower PEG-ASP formulation immunogenicity, few studies with conflict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::494d3155c082978deddecfa85e50b5b8
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19949
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19949
Autor:
M Sánchez Celma, E Iglesias Jimenez, A Comes Escoda, J Arrojo Suárez, M Rodriguez Reyes, J Antón López, C Latre Gorbe, F Bossacoma Busquets
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Tocilizumab is a humanised anti-interleukin-6 receptor monoclonal antibody. Intravenous tocilizumab is approved for use in children aged 2 years or older with polyarticular juvenile idiopathic arthritis (PJIA). Recently, sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a33790d63ace399acdd233d6b546fe4
https://doi.org/10.1136/ejhpharm-2020-eahpconf.29
https://doi.org/10.1136/ejhpharm-2020-eahpconf.29
Autor:
Alba Mesa Tudel, Martina Comes Escoda, José Tomás Navarro Ferrando, José María Ribera Santasusana
Publikováno v:
Medicina Clínica (English Edition). 157:408
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61224503aeb9353e3e1b21751f7784a8
https://doi.org/10.1016/j.medcle.2020.12.026
https://doi.org/10.1016/j.medcle.2020.12.026
Autor:
JL Vinent Genestar, J Arrojo Suárez, A Martínez Deyà, L Alsina Manrique de Lara, F Bossacoma Busquets, M Pallares Borras, AD Madrid Aris, A Comes Escoda, M Sánchez Celma
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Rituximab is a monoclonal antibody directed against the CD20 antigen, expressed on the surface of B-lymphocytes, promoting the lyses of the cells. It is labelled for adult different indications, non-Hodgkin’s lymphoma, chronic lymphocyti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab7d383efba93a232596a0aa54c4a0ba
https://doi.org/10.1136/ejhpharm-2019-eahpconf.339
https://doi.org/10.1136/ejhpharm-2019-eahpconf.339
Autor:
F Bossacoma Busquets, A Comes Escoda, L Alsina Manrique de Lara, Na Julia Palacios, A Deya Martinez, J Arrojo Suárez, T Lozano Andreu, M Sánchez Celma
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Intravenous immunoglobulins (IVIG) indications are replacement therapy and as immunomodulatory therapy for several autoimmune disorders. It has been estimated that neurologic indications can account for up to 43% of IVIG used in clinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22c387aac960278a815bad1121807cac
https://doi.org/10.1136/ejhpharm-2019-eahpconf.250
https://doi.org/10.1136/ejhpharm-2019-eahpconf.250
Publikováno v:
Eur J Hosp Pharm
Background The MAPK-pathway is a signal transduction cascade involved in the uncontrolled proliferation of many cancers. Mutations that activate these pathways occur in more than 90% of melanomas. This has led to the development of dabrafenib and vem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71ebf7e3e0dc5bba48d46212df0910e2
https://europepmc.org/articles/PMC7535162/
https://europepmc.org/articles/PMC7535162/